We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gut “Memory” May Explain Why IBD Flares Return

By LabMedica International staff writers
Posted on 28 Aug 2026

Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are characterized by recurring flare-ups that damage the intestinal mucosa and remain difficult to predict. More...

Although acute intestinal injury often precedes these conditions, the mechanisms that transform temporary damage into chronic inflammation are not fully understood. Clinicians also lack reliable markers to determine whether apparently healed tissue remains at risk. New findings show that lasting changes in the gut’s extracellular matrix can encode an inflammatory “memory” that alters stem cell fate long after symptoms have subsided.

Researchers at the Weizmann Institute of Science investigated whether short-lived intestinal inflammation leaves lasting imprints in the extracellular matrix (ECM), the protein-sugar scaffold surrounding epithelial cells. In mouse models of acute colitis, they tracked tissue architecture and ECM properties for more than a year after clinical recovery. The team also used miniature three-dimensional intestinal organoids grown from stem cells, along with single-cell RNA sequencing (scRNA-seq) resources and seven biopsies from patients with ulcerative colitis, to probe how ECM alterations influence epithelial differentiation.

The study identified collagen 18 as a key mediator of this inflammatory imprint. According to the authors, collagen 18 can trap signaling molecules within the ECM, disrupting pathways that normally direct stem cells to rebuild healthy epithelium and instead biasing them toward pro-inflammatory epithelial states. Silencing collagen 18 expression in mice prevented the ECM from sustaining irreversible damage and halted progression to chronic disease, supporting a causal role for ECM remodeling in persistent inflammation.

Even after the animals appeared to recover, the ECM remained less stiff, more porous, and disorganized at 80 and 400 days, revealing a long-lasting “memory” within the tissue microenvironment. Organoids grown on the disrupted ECM formed malformed sheets rather than normal crypt–villus structures, while transcriptomic profiling showed that the cells matured into inflammation-promoting epithelial states that recruit immune cells.

Published August 26, 2026, in Immunity, the findings suggest that the ECM acts as a “logistics hub” that stores and regulates signaling cues, with potential implications for predicting flare-prone regions and identifying therapeutic targets such as collagen 18.

“Growing stem cells as organoids within a disrupted extracellular matrix was enough to change their fate. Using a single-cell RNA sequencing database and seven biopsies from patients with ulcerative colitis, we found that these same pro-inflammatory epithelial cells also characterize inflamed regions in patients. These findings make it clear that the extracellular matrix plays a critical role in chronic inflammation and could potentially make it possible to predict which regions will develop inflammation or experience a future flare-up. More broadly, the new study reveals just how central the ECM is in creating a microenvironment, or niche, that supports stem cell regeneration,” said Dr. Moshe Biton of the Weizmann Institute of Science.

Related Links
Weizmann Institute of Science

 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.